Inhaled Dual PDE3/4 Inhibitor Ensifentrine for Chronic Obstructive Pulmonary Disease: A Potential Therapeutic Perspective-Reference-Cited by-同舟云学术

Inhaled Dual PDE3/4 Inhibitor Ensifentrine for Chronic Obstructive Pulmonary Disease: A Potential Therapeutic Perspective

Published:2024-01-15 Issue:2 Volume:209 Page:223-224
ISSN:1073-449X
Container-title:American Journal of Respiratory and Critical Care Medicine
language:en
Short-container-title:Am J Respir Crit Care Med

Author:

Gan Qiming¹,Wu Yanjuan¹,Su Xiaofen¹,Wang Jingcun¹,Zhang Haojie¹,Zhang Nuofu¹^ORCID,Wu Kang¹^ORCID

Affiliation:

1. State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, National Center for Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, People’s Republic of China

Funder

Young Scientist Fund of National Natural Science Foundation of China

Publisher

American Thoracic Society

Subject

Critical Care and Intensive Care Medicine,Pulmonary and Respiratory Medicine

Link

https://www.atsjournals.org/doi/pdf/10.1164/rccm.202307-1143LE

Reference7 articles.

1. Phosphodiesterases as therapeutic targets for respiratory diseases

2. Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (the ENHANCE Trials)

3. Inhaled Phosphodiesterase Inhibitors for the Treatment of Chronic Obstructive Pulmonary Disease

4. Inhaled corticosteroids in COPD: friend or foe?

5. The Phosphodiesterase Inhibitor Ensifentrine Reduces Production of Proinflammatory Mediators in Well Differentiated Bronchial Epithelial Cells by Inhibiting PDE4

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Polymorphism, phase transition, and physicochemical property investigation of Ensifentrine;CrystEngComm;2024